Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation

N R Waugh, E Cummins, P L Royle, C Clar, M Marien, B Richter, S Philip

Research output: Contribution to journalArticle

139 Citations (Scopus)

Abstract

In May 2008, the National Institute for Health and Clinical Excellence (NICE) issued an updated guideline [clinical guideline (CG) 66] for the management of all aspects of type 2 diabetes. This report aims to provide information on new drug developments to support a 'new drugs update' to the 2008 guideline.
Original languageEnglish
Pages (from-to)1-248
Number of pages248
JournalHealth Technology Assessment
Volume14
Issue number36
DOIs
Publication statusPublished - Jul 2010

Fingerprint

Type 2 Diabetes Mellitus
Cost-Benefit Analysis
Blood Glucose
Guidelines
National Institutes of Health (U.S.)
Pharmaceutical Preparations

Keywords

  • adamantane
  • body weight
  • cost-benefit analysis
  • diabetes mellitus, type 2
  • dipeptidyl-peptidase IV inhibitors
  • glucagon-like peptide 1
  • Great Britain
  • hemoglobin A, glycosylated
  • humans
  • hypoglycemic agents
  • insulin
  • nitriles
  • peptides
  • pyrazines
  • pyrrolidines
  • quality of life
  • randomized controlled trials as topic
  • state medicine
  • thiazolidinediones
  • triazoles
  • venoms

Cite this

Newer agents for blood glucose control in type 2 diabetes : systematic review and economic evaluation. / Waugh, N R; Cummins, E; Royle, P L; Clar, C; Marien, M; Richter, B; Philip, S.

In: Health Technology Assessment, Vol. 14, No. 36, 07.2010, p. 1-248.

Research output: Contribution to journalArticle

Waugh, N R ; Cummins, E ; Royle, P L ; Clar, C ; Marien, M ; Richter, B ; Philip, S. / Newer agents for blood glucose control in type 2 diabetes : systematic review and economic evaluation. In: Health Technology Assessment. 2010 ; Vol. 14, No. 36. pp. 1-248.
@article{4b737244a7ed4b3dac34c0a396200a5b,
title = "Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation",
abstract = "In May 2008, the National Institute for Health and Clinical Excellence (NICE) issued an updated guideline [clinical guideline (CG) 66] for the management of all aspects of type 2 diabetes. This report aims to provide information on new drug developments to support a 'new drugs update' to the 2008 guideline.",
keywords = "adamantane, body weight, cost-benefit analysis, diabetes mellitus, type 2, dipeptidyl-peptidase IV inhibitors, glucagon-like peptide 1, Great Britain, hemoglobin A, glycosylated, humans, hypoglycemic agents, insulin, nitriles, peptides, pyrazines, pyrrolidines, quality of life, randomized controlled trials as topic, state medicine, thiazolidinediones, triazoles, venoms",
author = "Waugh, {N R} and E Cummins and Royle, {P L} and C Clar and M Marien and B Richter and S Philip",
year = "2010",
month = "7",
doi = "10.3310/hta14360",
language = "English",
volume = "14",
pages = "1--248",
journal = "Health Technology Assessment",
issn = "1366-5278",
publisher = "National Co-ordinating Centre for HTA",
number = "36",

}

TY - JOUR

T1 - Newer agents for blood glucose control in type 2 diabetes

T2 - systematic review and economic evaluation

AU - Waugh, N R

AU - Cummins, E

AU - Royle, P L

AU - Clar, C

AU - Marien, M

AU - Richter, B

AU - Philip, S

PY - 2010/7

Y1 - 2010/7

N2 - In May 2008, the National Institute for Health and Clinical Excellence (NICE) issued an updated guideline [clinical guideline (CG) 66] for the management of all aspects of type 2 diabetes. This report aims to provide information on new drug developments to support a 'new drugs update' to the 2008 guideline.

AB - In May 2008, the National Institute for Health and Clinical Excellence (NICE) issued an updated guideline [clinical guideline (CG) 66] for the management of all aspects of type 2 diabetes. This report aims to provide information on new drug developments to support a 'new drugs update' to the 2008 guideline.

KW - adamantane

KW - body weight

KW - cost-benefit analysis

KW - diabetes mellitus, type 2

KW - dipeptidyl-peptidase IV inhibitors

KW - glucagon-like peptide 1

KW - Great Britain

KW - hemoglobin A, glycosylated

KW - humans

KW - hypoglycemic agents

KW - insulin

KW - nitriles

KW - peptides

KW - pyrazines

KW - pyrrolidines

KW - quality of life

KW - randomized controlled trials as topic

KW - state medicine

KW - thiazolidinediones

KW - triazoles

KW - venoms

U2 - 10.3310/hta14360

DO - 10.3310/hta14360

M3 - Article

C2 - 20646668

VL - 14

SP - 1

EP - 248

JO - Health Technology Assessment

JF - Health Technology Assessment

SN - 1366-5278

IS - 36

ER -